European researchers explore using patient-reported outcome tool to monitor radiotherapy side effects

Share this content:

Radiotherapy is the primary treatment options for unresectable lung cancer. However, the modality is associated with a range of side effects, including fatigue and inflammation of the esophagus and lungs.

Current methods to record treatment-related toxicities rely on assessment by health care professionals. Now a team from The University of Manchester and The Christie NHS Foundation Trust, which are both part of the Manchester Cancer Research Centre in the United Kingdom, has explored the use of patient-reported outcomes to improve the recording of side effects for lung cancer patients.

"Such patient-reported outcome tools have been mainly evaluated for use with chemotherapy treatments. We wanted to assess their feasibility and relevance in lung cancer patients undergoing radiotherapy," said research team leader Corinne Faivre-Finn, MD, PhD, a researcher in The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust.

The group looked at the agreement between side effects as reported by doctors and the patients themselves. They also evaluated the relationship between reported toxicities and quality-of-life measures, relating to aspects such as tiredness, anxiety, and shortness of breath.

Patients were asked to complete questionnaires covering both side effects and quality of life at three time points: before treatment, at the end of radiotherapy, and at later follow up. The consultants answered questions at identical time points covering the same common radiotherapy-related toxicities for each patient.

The study found that agreement was strongest between the patient's scoring of side effects and measures relating to their quality of life. Toxicities as recorded by the clinicians appeared to underestimate their severity.

"This was the first study in Europe to explore such a patient-centered approach to recording side effects. Incorporating this method into cancer care could allow us to detect and manage serious effects earlier. It could also improve patient-doctor relationships and help doctors better understand the full impact of treatment on patients," said Faivre-Finn.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs